Anti-hsp70 antibody

A novel anti-Hsp70 antibody targeting the 461-490 region of Hsp70 on cell membranes shows promising antitumor effects, addressing the scarcity of effective antibodies for cancer treatment and diagnosis by specifically binding to cell membrane HSP70, demonstrating efficacy in reducing tumor growth and cell proliferation.

WO2024242202A1PCT designated stage expired Publication Date: 2024-11-28PUBLIC UNIVERSITY CORPORATION OSAKA CITY UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019305
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is a lack of effective antibodies targeting Hsp70 for cancer diagnosis and treatment, with existing options not adequately addressing the need for specific binding to cell membrane HSP70 for antitumor effects.

Method used

Development of a specific anti-Hsp70 antibody that recognizes the region corresponding to positions 461 to 490 of the Hsp70 protein, binding preferentially to cell membrane Hsp70, and exhibiting a surprising antitumor effect in vitro and in vivo, with detailed specifications of its heavy and light chain complementarity determining regions and production methods.

Benefits of technology

The antibody demonstrates significant antitumor activity, particularly in pancreatic cancer, as shown by reduced tumor weight and cell proliferation inhibition, and can be used as a standalone antitumor agent or in antigen test kits, with potential applications in various tumor diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

The purpose of the present invention is to provide a new useful antibody against Hsp70. This anti-Hsp70 antibody recognizes a region, in Hsp70 protein, corresponding no. 461-490 in SEQ ID NO. 1, or has: as heavy chain complementation determination regions, HCDR1 having an amino acid sequence of no. 45-56, no. 50-56, or no. 45-54 in SEQ ID NO. 2, HCDR2 having an amino acid sequence of no. 71-86 or no. 72-78 in SEQ ID NO. 2, and HCDR3 having an amino acid sequence of no. 117-128 or no. 119-128 in SEQ ID NO. 2; and, as light chain complementation determination regions, LCDR1 having an amino acid sequence of no. 43-53 in SEQ ID NO. 15 or of no. 43-54, no. 47-52, no. 50-52, or no. 50-53 in SEQ ID NO. 3, LCDR2 having an amino acid sequence of no. 70-76, no. 70-71, or no. 70-75 in SEQ ID NO. 3, and LCDR3 having an amino acid sequence of no. 109-117 in SEQ ID NO. 3.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-Hsp70 antibody

[0001] The present invention relates to anti-Hsp70 antibodies.

[0002] Heat shock proteins (Hsps) are a highly conserved protein family that function as molecular chaperones that play important roles in intracellular protein homeostasis, regulating apoptosis, and protecting against various stressors (hypoxia, heat stress, oxidative stress, etc.). Among Hsps, proteins such as HSP40, HSP60, HSP70, and HSP90 are known to be localized in the plasma membrane of malignantly transformed cells (Non-Patent Document 1).

[0003] Currently, an anti-cell membrane HSP70 antibody is commercially available as a useful antibody against Hsp70 (Non-Patent Document 2). This antibody has the property of binding very little to intracellular HSP70 but specifically to cell membrane HSP70, and is therefore used in cancer research.

[0004] Cells 2020, 9, 1263. Anti-Cell Membrane HSP70 Antibody <Anti-Heat Shock Protein 70> [online], June 12, 2020, Funakoshi Co., Ltd. [Retrieved May 8, 2023], Internet <URL: https: / / www.funakoshi.co.jp / contents / 65741>

[0005] Although proteins such as Hsp70 are expected to be targets for cancer diagnosis or treatment, there are not enough useful antibody options available. Therefore, an object of the present invention is to provide a new useful antibody against Hsp70.

[0006] The present inventors conducted extensive screening of anti-Hsp70 antibodies from 2,700 hybridoma clones obtained by the lymph node assay, and selected an antibody that barely exhibited a slight antitumor effect in vitro. Examination of this selected antibody confirmed that it hardly bound to intracellular Hsp70, but specifically bound to cell membrane Hsp70. Furthermore, when this selected antibody was purified and its antitumor effect was examined in vitro and in vivo, it was confirmed to exhibit a remarkable antitumor effect. Based on this finding, further investigation led to the completion of the present invention.

[0007] That is, the present invention provides the following aspects: Item 1. An anti-Hsp70 antibody that recognizes a region of the Hsp70 protein corresponding to positions 461 to 490 of SEQ ID NO: 1. Item 2. The anti-Hsp70 antibody according to Item 1, which binds to Hsp70 on the cell membrane. Item 3. An anti-Hsp70 antibody having, as heavy chain complementarity determining regions, an HCDR1 consisting of the amino acid sequence of positions 45 to 56, 50 to 56, or 45 to 54 of SEQ ID NO:2, an HCDR2 consisting of the amino acid sequence of positions 71 to 86 or 72 to 78 of SEQ ID NO:2, and an HCDR3 consisting of the amino acid sequence of positions 117 to 128 or 119 to 128 of SEQ ID NO:2; and, as light chain complementarity determining regions, an LCDR1 consisting of the amino acid sequence of positions 43 to 54, 47 to 52, 50 to 52, or 50 to 53 of SEQ ID NO:3, or the amino acid sequence of positions 43 to 53 of SEQ ID NO:15, an LCDR2 consisting of the amino acid sequence of positions 70 to 76, 70 to 71, or 70 to 75 of SEQ ID NO:3, and an LCDR3 consisting of the amino acid sequence of positions 109 to 117 of SEQ ID NO:3. The anti-Hsp70 antibody of Item 3 can recognize a region of the Hsp70 protein corresponding to amino acids 461 to 490 of SEQ ID NO: 1. Item 4. The anti-Hsp70 antibody of Item 3, wherein the heavy chain variable region consists of the amino acid sequence of amino acids 21 to 139 of SEQ ID NO: 2 and the light chain variable region consists of the amino acid sequence of amino acids 21 to 127 of SEQ ID NO: 3. Item 5. The anti-Hsp70 antibody of Item 3, wherein the heavy chain variable region consists of the amino acid sequence of amino acids 21 to 139 of SEQ ID NO: 13 and the light chain variable region consists of the amino acid sequence of amino acids 21 to 127 of SEQ ID NO: 14 or the amino acid sequence of amino acids 21 to 127 of SEQ ID NO: 15. Item 6. The anti-Hsp70 antibody of any one of Items 1 to 5, which is an isolated monoclonal antibody. Item 7. The anti-Hsp70 antibody of Item 6, wherein the monoclonal antibody is a human chimeric antibody or a humanized antibody. Item 8. Item 9. An antitumor agent comprising the anti-Hsp70 antibody of any one of Items 1 to 7. Item 10. The antitumor agent of Item 8, which is used for pancreatic cancer. Item 11. An antigen test kit comprising the anti-Hsp70 antibody of any one of Items 1 to 7.Item 12. A nucleic acid encoding the anti-Hsp70 antibody according to any one of Items 3 to 5. Item 13. An expression cassette or recombinant vector comprising the nucleic acid according to Item 12. Item 14. A transformant obtained by transforming a host with the expression cassette or recombinant vector according to Item 13. Item 15. A method for producing an anti-Hsp70 antibody, comprising the step of culturing the transformant according to Item 14.

[0008] According to the present invention, a new useful antibody against Hsp70 is provided.

[0009] Figure 1 shows the results of Western blot of GST fusion proteins of human Hsp70 (HSPA1A) fragments (Fr5-1, Fr5-2, Fr5-3) with antibody 7H8 (the anti-Hsp70 antibody of the present invention) or an anti-GST antibody. Figure 2 shows the time course of luciferase activity derived from pancreatic cancer cells when 20 mg / kg of mouse IgG or antibody 7H8 (the anti-Hsp70 antibody of the present invention) was administered to mice bearing human pancreatic cancer cells PANC-1 expressing a luciferase gene. Figure 3 shows the results of in vivo imaging of luciferase activity of primary lesions 4 weeks after administration of the antibodies in Figure 2. Figure 4 shows the tumor weight 4 weeks after administration of the antibodies in Figure 2. Figure 5 shows the results of immunostaining human pancreatic ductal adenocarcinoma tissue with antibody 7H8 (the anti-Hsp70 antibody of the present invention). Figure 6 shows the results of immunostaining human lung squamous cell carcinoma tissue with antibody 7H8 (the anti-Hsp70 antibody of the present invention). Figure 1 shows the in vitro cell proliferation inhibitory effect of antibody 7H8 (the anti-Hsp70 antibody of the present invention) on human pancreatic cancer cells PANC-1. Figure 2 shows the results of SDS-PAGE and CBB staining demonstrating the production of a mouse IgG antibody (the anti-Hsp70 antibody of the present invention) of antibody 7H8 (mouse IgM, the anti-Hsp70 antibody of the present invention). Figure 3 shows the calculation results of the KD value of the mouse IgG antibody of antibody 7H8 (the anti-Hsp70 antibody of the present invention). Figure 4 shows the results of dot blot analysis of culture supernatant obtained after 4 days of culture in HEK293 cells transfected with a vector expressing a humanized IgG antibody of antibody 7H8 (the anti-Hsp70 antibody of the present invention). Figure 5 shows the results of immunostaining PANC-1 cells that have acquired gemcitabine resistance due to long-term administration of the anticancer drug gemcitabine, using the humanized IgG of 7H8 antibody or mouse IgM (both anti-Hsp70 antibodies of the present invention).

[0010] 1. Anti-Hsp70 Antibodies The anti-Hsp70 antibodies of the present invention can be specified as antibodies that recognize a specific epitope in the Hsp70 protein. The Hsp70 targeted by the anti-Hsp70 antibodies of the present invention is not particularly limited as long as it has the specific epitope, and may be either constitutive or inducible. Specific examples of target Hsp70 include the proteins shown in the table below (representative names include Hsp70-1a, Hsp70-1b, Hsp70-1t, Hsp70-2, Hsp70-5, Hsp70-6, HSC70, and Hsp70-9), with Hsp70-1a and Hsp70-1b being preferred.

[0011]

[0012] The predetermined epitope recognized by the anti-Hsp70 antibody of the present invention is a region corresponding to positions 461 to 490 of SEQ ID NO: 1. SEQ ID NO: 1 is the amino acid sequence of Hsp70-1a. In the present invention, the predetermined epitope is a region corresponding to positions 461 to 490 of SEQ ID NO: 1, and includes not only the amino acid sequence consisting of positions 461 to 490 of SEQ ID NO: 1, but also amino acid sequences having 70% or more sequence identity thereto. The region corresponding to positions 461 to 490 of SEQ ID NO: 1 can be easily identified by aligning the amino acid sequence of Hsp70-1a (SEQ ID NO: 1) with the amino acid sequences of, for example, Hsp70-1b, Hsp70-1t, Hsp70-2, Hsp70-5, Hsp70-6, HSC70, Hsp70-9, etc.

[0013] Specifically, examples of the region corresponding to positions 461 to 490 of SEQ ID NO: 1 (predetermined epitopes) include the following [a] to [h]. [a] A region consisting of the 461st to 490th amino acid sequence of Hsp70-1a (SEQ ID NO: 1) [b] A region consisting of the 461st to 490th amino acid sequence of Hsp70-1b (SEQ ID NO: 4) [c] A region consisting of the 463rd to 492nd amino acid sequence of Hsp70-1t (SEQ ID NO: 5) [d] A region consisting of the 464th to 493th amino acid sequence of Hsp70-2 (SEQ ID NO: 6) [e] A region consisting of the 484th to 513th amino acid sequence of Hsp70-5 (SEQ ID NO: 7) [f] A region consisting of the 463rd to 492nd amino acid sequence of Hsp70-6 (SEQ ID NO: 8) [g] A region consisting of the 461st to 490th amino acid sequence of HSC70 (SEQ ID NO: 9) [h] A region consisting of the 505th to 534th amino acid sequence of Hsp70-9 (SEQ ID NO: 10)

[0014] The above regions [a] and [b] have the same sequence as the amino acid sequence consisting of amino acids 461 to 490 of SEQ ID NO: 1. The above regions [c] to [h] have 70% or more sequence identity with the amino acid sequence consisting of amino acids 461 to 490 of SEQ ID NO: 1. In the present invention, preferred examples of the region corresponding to amino acids 461 to 490 of SEQ ID NO: 1 (predetermined epitope) include the above regions [a] and [b].

[0015] An example of an anti-Hsp70 antibody of the present invention is an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 2 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 3. The frameworks in SEQ ID NOs: 2 and 3 are derived from mouse.

[0016] SEQ ID NO: 2 consists of a signal sequence from positions 1 to 20 and a heavy chain variable region (VH) from positions 21 to 139, and SEQ ID NO: 3 consists of a signal sequence from positions 1 to 20 and a light chain variable region (VL) from positions 21 to 127.

[0017] Another example of the anti-Hsp70 antibody of the present invention is an antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 13 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 14 or 15. The frameworks in SEQ ID NOs: 13 to 15 are of human origin.

[0018] SEQ ID NO: 13 consists of a signal sequence from positions 1 to 20 and a heavy chain variable region (VH) from positions 21 to 139; SEQ ID NO: 14 consists of a signal sequence from positions 1 to 20 and a light chain variable region (VL) from positions 21 to 127; and SEQ ID NO: 15 consists of a signal sequence from positions 1 to 20 and a light chain variable region (VL) from positions 21 to 127.

[0019] The heavy chain complementarity determining regions in the heavy chain variable region (VH) and the light chain complementarity determining regions in the light chain variable region (VL) are shown below with complementarity determining regions (CDRs) defined by all combinations (Kabat / IMGT) of the Kabat numbering program (Bioinformatics, 32, 298-300 (2016)) and the IMGT system (Dev Comp Immunol. 27, 55-77 (2003)), CDRs defined by the Kabat numbering program, and CDRs defined by the IMGT system.

[0020]

[0021] Accordingly, the anti-Hsp70 antibodies of the present invention may be specified as antibodies having the following complementarity determining regions (CDRs): [HCDR] Heavy chain complementarity determining region HCDR1 consisting of the amino acid sequence of positions 45 to 56, 50 to 56, or 45 to 54 of SEQ ID NO: 2, HCDR2 consisting of the amino acid sequence of positions 71 to 86, or 72 to 78 of SEQ ID NO: 2, and HCDR3 consisting of the amino acid sequence of positions 117 to 128, or 119 to 128 of SEQ ID NO: 2. [LCDR] Light chain complementarity determining region LCDR1 consisting of the amino acid sequence of positions 43 to 54, 47 to 52, 50 to 52, or 50 to 53 of SEQ ID NO: 3, or positions 43 to 53 of SEQ ID NO: 15, LCDR2 consisting of the amino acid sequence of positions 70 to 76, 70 to 71, or 70 to 75 of SEQ ID NO: 3, and LCDR3 consisting of the amino acid sequence of positions 109 to 117 of SEQ ID NO: 3.

[0022] In the anti-Hsp70 antibodies of the present invention, the regions other than the CDRs (signal sequence and framework sequence) are not particularly limited, as long as they do not impair the binding activity to a specific epitope of Hsp70, preferably the anti-tumor activity in addition to the binding activity. Specific amino acid sequences constituting the regions other than the CDRs include amino acid sequences that share 80% or more sequence identity with the signal sequence (the sequence of amino acids 1 to 19 of SEQ ID NO: 2 and the sequence of amino acids 1 to 20 of SEQ ID NO: 3), which are regions other than the CDRs in SEQ ID NOs: 2 and 3, and the framework sequences (the amino acid sequence connecting HCDR1 and HCDR2 of SEQ ID NO: 2, the amino acid sequence connecting HCDR2 and HCDR3 of SEQ ID NO: 2, the amino acid sequence connecting LCDR1 and LCDR2 of SEQ ID NO: 3, and the amino acid sequence connecting LCDR2 and LCDR3 of SEQ ID NO: 3).

[0023] Preferred examples of the above-mentioned sequence identity of 80% or more may vary depending on the full length of the reference sequence, but include preferably 85% or more, more preferably 90% or more, even more preferably 92% or more, even more preferably 94% or more or 95% or more, still more preferably 96% or more or 97% or more, and most preferably 100%.

[0024] The term "sequence identity" refers to the amino acid sequence identity value obtained by the bl2seq program (Tatiana A. Tatsusova, Thomas L. Madden, FEMS Microbiol. Lett., Vol. 174, pp. 247-250, 1999) of BLAST PACKAGE [sgi32 bit edition, Version 2.0.12; available from the National Center for Biotechnology Information (NCBI)]. The parameters are set as follows: Gap insertion cost value: 11, Gap extension cost value: 1.

[0025] In the above amino acid sequences with a sequence identity of 80% or more but less than 100%, when a specific amino acid is substituted in each of the amino acid sequences of the signal sequence shown in SEQ ID NOs: 2 and 3 (the sequence of amino acids 1 to 20 of SEQ ID NO: 2 and the sequence of amino acids 1 to 20 of SEQ ID NO: 3) and the framework sequence shown in SEQ ID NOs: 2 and 3 (the amino acid sequence connecting HCDR1 and HCDR2 of SEQ ID NO: 2, the amino acid sequence connecting HCDR2 and HCDR3 of SEQ ID NO: 2, and the amino acid sequence connecting LCDR1 and LCDR2 of SEQ ID NO: 3, and the amino acid sequence connecting LCDR2 and LCDR3 of SEQ ID NO: 3), substitution with a similar amino acid (i.e., conservative amino acid substitution) is preferred because it is predicted not to cause any change in the neutralizing activity of the antibody. Specifically, the following classifications have been established based on the properties of the amino acid side chain, and substitution with an amino acid belonging to the same classification is preferred. Basic amino acids: lysine, arginine, histidine Acidic amino acids: glutamic acid, aspartic acid Neutral amino acids: glycine, alanine, serine, threonine, methionine, cysteine, phenylalanine, tryptophan, tyrosine, leucine, isoleucine, valine, glutamine, asparagine, proline Furthermore, the neutral amino acids can be classified into those with polar side chains (asparagine, glutamine, serine, threonine, tyrosine, cysteine), those with nonpolar side chains (glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), those with amide-containing side chains (asparagine, glutamine), those with sulfur-containing side chains (methionine, cysteine), those with aromatic side chains (phenylalanine, tryptophan, tyrosine), those with hydroxyl-containing side chains (serine, threonine, tyrosine), and those with aliphatic side chains (alanine, leucine, isoleucine, valine).

[0026] Methods for substituting a predetermined amino acid in an amino acid sequence with another amino acid include, for example, site-directed mutagenesis (Hashimoto-Gotoh T. et al., Gene, Vol. 152, pp. 271-275 (1995); Zoller MJ. et al., Methods Enzymol. Vol. 100, pp. 468-500 (1983); Kramer W. et al., Nucleic Acids Res. Vol. 12, pp. 9441-9456 (1984); Kramer W. et al., Methods Enzymol. Vol. 154, pp. 350-367 (1987); Kunkel TA., Proc. Natl Acad Sci USA., Vol. 82, pp. 488-492 (1985), etc., are known, and amino acid substitutions can be made in the amino acid sequence of a CDR using this site-directed mutagenesis method. Methods for substituting with other amino acids also include the library technology described in WO2005 / 080432.

[0027] The isotype of the anti-Hsp70 antibody of the present invention is not particularly limited, and examples include IgG (IgG1, IgG2, IgG3, IgG4), IgA (IgA1, IgA2), IgM, IgD, and IgE.

[0028] The form of the anti-Hsp70 antibody of the present invention is typically an isolated monoclonal antibody. The method for producing monoclonal antibodies is not particularly limited, and examples thereof include the hybridoma method described in "Kohler G, Milstein C., Nature. 1975 Aug. 7; 256(5517): 495-497."; the recombinant method described in U.S. Pat. No. 4,816,567; the method of isolation from a phage antibody library described in "Clackson et al., Nature. 1991 Aug. 15; 352(6336): 624-628." or "Marks et al., J. Mol. Biol. 1991 Dec. 5; 222(3): 581-597."; and the method described in "Protein Experiment Handbook, Yodosha (2003): 92-96."

[0029] Monoclonal antibodies include human chimeric antibodies and humanized antibodies. Human chimeric antibodies are antibodies in which the variable region amino acid sequences, including framework sequences and CDR sequences, are of non-human origin and the constant region is of human origin. Humanized antibodies are antibodies in which only the CDR sequences are of non-human origin and the other regions are of human origin. Since the antigen specificity of humanized antibodies is conferred by the non-human CDRs, the CDR amino acid sequences should be used essentially unchanged, and only minor modifications that do not significantly interfere with the affinity and specificity of the antibody for its target antigen are permitted. The method for producing humanized antibodies is not particularly limited, and they can be designed and produced, for example, by the method described in "Kuramochi T, Igawa T, Tsunoda H and Hattori K., Methods Biol. 2014;1060:123-137."

[0030] Furthermore, the anti-Hsp70 antibody of the present invention includes not only full-length antibodies (antibodies having Fab and Fc regions) but also fragment antibodies. Examples of such fragment antibodies include Fv antibodies, Fab antibodies, Fab' antibodies, and F(ab') antibodies. 2Examples of the anti-Hsp70 antibodies of the present invention include monoclonal antibodies, scFv antibodies, dsFv antibodies, diabodies, nanobodies, etc. The anti-Hsp70 antibodies of the present invention also include multispecific antibodies (e.g., bispecific antibodies) as long as they contain the above-mentioned variable regions. These antibody fragments and multispecific antibodies can be prepared according to conventional methods.

[0031] The anti-Hsp70 antibody of the present invention may be a conjugated antibody or a conjugated antibody fragment bound to various compounds such as polyethylene glycol, radioactive substances, toxins, etc. Furthermore, the sugar chain bound to the anti-Hsp70 antibody of the present invention may be modified, or other proteins may be fused thereto, as necessary.

[0032] The anti-Hsp70 antibodies of the present invention preferably bind to Hsp70 on the cell membrane of cells such as cancer cells. Antibodies of the present invention that bind to cell membrane Hsp70 can be selected by immunofluorescence staining using cells such as cancer cells.

[0033] 2. Nucleic Acids The present invention also provides nucleic acids encoding the above-described anti-Hsp70 antibodies. The nucleic acids of the present invention can be obtained, for example, by using the above-described nucleic acids encoding the anti-Hsp70 antibodies as a template to obtain at least the region encoding the anti-Hsp70 antibodies by PCR or other methods. The nucleic acids of the present invention can also be artificially synthesized by gene synthesis methods.

[0034] Those skilled in the art can appropriately design the base sequences of the nucleic acids of the present invention based on the above-mentioned CDR sequences of the anti-Hsp70 antibodies of the present invention. For example, SEQ ID NO: 11 is an example of a base sequence that encodes SEQ ID NO: 2, and SEQ ID NO: 12 is an example of a base sequence that encodes SEQ ID NO: 3. Therefore, the base sequences of the nucleic acids of the present invention can be designed using the regions that encode the respective CDRs contained in these base sequences.

[0035] 3. Expression Cassette or Recombinant Vector The expression cassette or recombinant vector of the present invention comprises the nucleic acid of the present invention described above in "2. Nucleic Acid." The expression cassette or recombinant vector of the present invention can be obtained by linking a promoter and a terminator to the nucleic acid of the present invention, or by inserting the expression cassette of the present invention or the nucleic acid of the present invention into an expression vector.

[0036] The expression cassette or recombinant vector of the present invention includes a regulatory element such as a promoter operably linked to the nucleic acid of the present invention. A representative regulatory element is a promoter, but it may also include transcription elements such as an enhancer, a CCAAT box, a TATA box, or an SPI site, as necessary. "Operably linked" means that the nucleic acid of the present invention is linked to various regulatory elements such as a promoter or enhancer that regulate the nucleic acid of the present invention in a state that allows it to operate in a host cell.

[0037] Suitable expression vectors are those constructed for genetic recombination from phages, plasmids, or viruses that can autonomously replicate in a host. Specific examples include Escherichia coli-derived plasmids (e.g., pET-Blue), Bacillus subtilis-derived plasmids (e.g., pUB110), yeast-derived plasmids (e.g., pSH19), animal cell expression plasmids (e.g., pA1-11, pcDNA3.1-V5 / His-TOPO), bacteriophages such as λ phage, and virus-derived vectors.

[0038] 4. Transformant A transformant can be obtained by transforming a host with the expression cassette of the present invention described above in "3. Expression cassette or recombinant vector" or the above-mentioned recombinant vector.

[0039] The host used to produce the transformant is not particularly limited as long as it can be introduced with a gene, is capable of autonomous proliferation, and is capable of expressing the traits of the gene of the present invention. Examples of the host include cells of humans and mammals other than humans (e.g., rats, mice, guinea pigs, rabbits, cows, monkeys, etc.), more specifically, Chinese hamster ovary cells (CHO cells), monkey cells COS-7, human embryonic kidney cells (e.g., HEK293 cells); insect cells; plant cells; bacteria belonging to the genus Escherichia such as Escherichia coli, the genus Bacillus such as Bacillus subtilis, the genus Pseudomonas such as Pseudomonas putida, etc.; actinomycetes, etc.; yeast, etc.; and filamentous fungi.

[0040] A transformant can be obtained by introducing the expression cassette of the present invention or the recombinant vector of the present invention into a host. The location where the nucleic acid of the present invention is introduced is not particularly limited as long as the gene of interest can be expressed, and may be on a plasmid or on the genome. Specific methods for introducing the expression cassette of the present invention or the recombinant vector of the present invention include, for example, recombinant vector methods and genome editing methods.

[0041] Conditions for introducing an expression cassette or recombinant vector into a host may be appropriately set depending on the type of host, etc. When the host is a bacterium, examples include a method using competent cells treated with calcium ions and the electroporation method. When the host is a yeast, examples include electroporation, the spheroplast method, and the lithium acetate method. When the host is an animal cell, examples include electroporation, the calcium phosphate method, and the lipofection method. When the host is an insect cell, examples include the calcium phosphate method, the lipofection method, and the electroporation method. When the host is a plant cell, examples include electroporation, the Agrobacterium method, the particle gun method, and the PEG method.

[0042] 5. Method for Producing Anti-Hsp70 Antibody The method for producing an anti-Hsp70 antibody of the present invention is a method for producing an anti-Hsp70 antibody as described above in "1. Anti-Hsp70 Antibody," and includes the step of culturing the transformant of the present invention as described above in "4. Transformant." Culture conditions for the transformant may be appropriately set taking into consideration the nutritional and physiological properties of the host, but liquid culture is preferred. The anti-Hsp70 antibody can be appropriately recovered and purified from the resulting culture.

[0043] 6. Antitumor Agents The present invention also provides antitumor agents comprising the anti-Hsp70 antibodies described above in "1. Anti-Hsp70 antibodies."

[0044] The antitumor agent of the present invention is typically prepared in the form of a pharmaceutical composition containing the anti-Hsp70 antibody as an active ingredient. The antitumor agent of the present invention may contain an effective amount of the anti-Hsp70 antibody, and may also contain pharmaceutically acceptable carriers or additives. Examples of such carriers or additives include surfactants, excipients, colorants, flavorings, preservatives, stabilizers, buffers, pH buffers, disintegrants, solubilizers, solubilizers, isotonicity agents, binders, disintegrants, lubricants, diluents, and flavoring agents.

[0045] The antitumor agent of the present invention may contain other antitumor drugs in addition to the anti-Hsp70 antibody. However, since the anti-Hsp70 antibody has an excellent antitumor effect, a preferred embodiment of the antitumor agent of the present invention does not contain other antitumor drugs.

[0046] Furthermore, the method of administration of the antitumor agent of the present invention may be either oral or parenteral, and specific examples of administration methods include oral administration; and parenteral administration such as intravenous administration, intramuscular administration, intraperitoneal administration, subcutaneous administration, nasal administration, pulmonary administration, transdermal administration, transmucosal administration, and intraocular administration.

[0047] The formulation of the antitumor agent of the present invention can be appropriately determined depending on the administration method to be adopted. For example, when used for oral administration, it may be prepared into formulations such as powder, granules, capsules, syrup, suspension, etc., and when used for parenteral administration, it may be prepared into formulations such as liquid, suspension, emulsion, spray, suppository, eye drops, etc.

[0048] The antitumor agent of the present invention can be preferably applied to humans or non-human animals (typically mammals).

[0049] The antitumor agent of the present invention can be used to treat any tumor disease, including liver cancer, stomach cancer, bladder cancer, pancreatic cancer, lung cancer, and gallbladder cancer, with pancreatic cancer being preferred.

[0050] The dose of the antitumor agent of the present invention is not particularly limited, but may be, for example, 0.5 to 5 mg / kg, preferably 0.8 to 3 mg / kg, more preferably 1 to 2 mg / kg per administration in humans.

[0051] When used to treat any tumor disease, the antitumor agent of the present invention can be used in combination with other drug therapies (chemotherapy, endocrine therapy (hormone therapy), molecular targeted therapy, etc.). However, because the anti-Hsp70 antibody has excellent antitumor effects, in a preferred embodiment of the antitumor agent of the present invention, it is used as a sole active ingredient without being used in combination with other drug therapies.

[0052] 7. Antigen Test Kit The present invention also provides an antigen test kit containing the anti-Hsp70 antibody described above in "1. Anti-Hsp70 antibody."

[0053] The anti-Hsp70 antibody may be immobilized on a water-insoluble carrier, which may be a particle or a substrate.

[0054] The specimen is not particularly limited as long as it is one for which detection of Hsp70 having a predetermined epitope is desired, and specific examples include body fluid samples such as blood and urine, and tissue samples such as tumor tissue.

[0055] The antigen test kit of the present invention can be constructed based on a method of immunoassay (a representative example is enzyme-linked immunosorbent assay (ELISA)) of the antigen-antibody reaction between the anti-Hsp70 antibody and the antigen in the sample.

[0056] The antigen test kit of the present invention may contain, in addition to the anti-Hsp70 antibody, other antibodies and / or other reagents and / or instruments corresponding to the measurement method.

[0057] The present invention will be explained in more detail below by showing examples, but the present invention is not limited to these examples.

[0058] Test Example 1 (1) Obtaining antibody 7H8 Anti-Hsp70 monoclonal antibody 7H8 (IgM), which was suggested to have a slight antitumor effect in vitro, was obtained by screening of anti-Hsp70 antibodies from 2,700 hybridoma clones obtained by the mouse lymph node assay using GST-Hsp70 as an antigen.

[0059] (2) Epitope Mapping of Antibody 7H8 (IgM) A fragment of human Hsp70 (HSPA1A) having the amino acid sequence shown in SEQ ID NO: 1 (Table 7) was inserted into pGEX-2TK to prepare a GST fusion protein.

[0060] The following ELISA was performed for epitope mapping. GST fusion proteins of each Hsp70 fragment listed in Table 7, full-length Hsp70, or full-length Hsc70 (a molecule of the same family (HspA8) with 86% homology to Hsp70) were diluted to 1 μL / mL in 20 mM sodium phosphate buffer (pH 7.2) and immobilized on a 96-well plate. After blocking with 1% BSA / TBS-T, hybridoma culture supernatant was added and the antibody reaction was allowed to proceed. After washing, the plate was reacted with HRP-conjugated anti-mouse IgM+IgG antibody. After washing, a substrate was added to develop color, and the absorbance at OD450 and OD570 was measured. The results are shown in Table 8.

[0061]

[0062] As shown in Table 8, Fr5 exhibited high absorbance, indicating that antibody 7H8 (IgM) binds to Fr5. Therefore, GST fusion proteins of further fragments of Fr5 (Fr5-1: 396-460, Fr5-2: 461-550, Fr5-3: 431-490) were prepared and subjected to Western blotting. The results are shown in Figure 1. In Figure 1, detected bands are marked with an asterisk (*). As shown in Figure 1, antibody 7H8 (IgM) bound to Fr5-2 (461-550) and Fr5-3 (431-490) but not to Fr5-1 (396-460), indicating that antibody 7H8 (IgM) binds to the 461-490 region of Hsp70 as an epitope. Furthermore, antibody 7H8 (IgM) also cross-reacted with the full-length Hsp70. Furthermore, a reaction was observed with Hsc70 (gene HSPA8) which has 86% homology at the amino acid level, suggesting that antibody 7H8 (IgM) may also cross-react with HSC70.

[0063] (3) Sequence analysis of antibody 7H8 (IgM) The heavy and light chain sequences of antibody 7H8 (IgM) were determined to be SEQ ID NO: 2 and SEQ ID NO: 3, respectively. SEQ ID NO: 2 consists of a signal sequence from residues 1 to 20 followed by a heavy chain variable region (VH), and SEQ ID NO: 3 consists of a signal sequence from residues 1 to 20 followed by a light chain variable region (VL). The sequence analysis results for SEQ ID NOs: 2 and 3, the heavy chain variable region (VH), and the light chain variable region (VL), as well as each CDR in those regions, are as follows: The CDR sequences shown include CDRs defined by all combinations (Kabat / IMGT) of the Kabat numbering program (Bioinformatics, 32, 298-300 (2016)) and the IMGT system (Dev Comp Immunol. 27, 55-77 (2003)), CDRs defined by the Kabat numbering program, and CDRs defined by the IMGT system.

[0064]

[0065]

[0066]

[0067] Test Example 2: Four 6-week-old female BALB / c Slc-nu / nu mice were used. Human pancreatic cancer cells PANC-1 stably expressing the luciferase gene were transplanted subcutaneously into the right dorsal skin of the mice at a rate of 10,000,000 cells. Starting one week after transplantation, tumor growth was assessed once per week using an IVIS (PerkinElmer). For IVIS measurements, images of the primary tumor were taken in the prone position 15 minutes after intraperitoneal administration of luciferin, followed immediately by images in the supine position to confirm the presence or absence of metastasis. Four weeks after transplantation, two mice with similar tumor sizes were selected and intraperitoneally administered 20 mg / kg of mouse IgG or antibody 7H8 (IgM) at 20 mg / kg (400 μg / mouse / dose, since the mice weighed 20 g) once per week for three weeks. Four weeks after antibody administration, the mice were sacrificed, the tumors were excised, and the tumor weights were measured.

[0068] The results of measuring luciferase activity derived from pancreatic cancer cells are shown in FIG. 1 (time course of luciferase activity) and FIG. 2 (measurement results at 4 weeks after antibody administration), and the results of measuring the weight of the excised tumors are shown in FIG.

[0069] As shown in Figures 1 and 2, in mice administered with antibody 7H8 (IgM), on the one hand, a marked reduction in tumor size was observed, and on the other hand, tumor disappearance was observed. This is also reflected in the results in Figure 3. In other words, antibody 7H8 (IgM) alone was found to have extremely high antitumor activity.

[0070] Test Example 3: Staining of human pancreatic ductal adenocarcinoma and lung squamous cell carcinoma was evaluated. Paraffin-embedded human cancer tissue blocks were thinly sectioned and deparaffinized, followed by antigen inactivation using microwaves and 3% hydrogen peroxide. VECTASTAIN ABC Kit Mouse IgM (VECTOR, PK-4010) was used for staining. After blocking, antibody 7H8 (IgM) was diluted 100-fold and incubated overnight for four cycles. After washing, the sections were incubated with a biotinylated secondary antibody for 30 minutes, reacted with ABC reagent, and then colored with DAB (3,3'-diaminobenzidine). After the reaction was stopped, the sections were washed, stained with hematoxylin, dehydrated, cleared, and mounted. Positive or negative results were determined based on the presence or absence of staining.

[0071] Positive results were observed in 4 out of 28 cases of pancreatic ductal adenocarcinoma (positive rate 14%) and 1 out of 30 cases of lung squamous cell carcinoma (positive rate 3%). An example of the staining results for pancreatic ductal adenocarcinoma is shown in Figure 4, and an example of the staining results for lung squamous cell carcinoma is shown in Figure 5.

[0072] Test Example 4: The inhibitory effect of antibody 7H8 (IgM) on PANC-1 proliferation was evaluated. 3,000 PANC-1 cells were seeded in a 96-well plate, and 24 hours later, control IgM or antibody 7H8 (IgM) was added at 5 μg / mL to a medium containing 1% FBS. Images were taken over time using an Incucyte ZOOM (SARTORIUS). Cell proliferation ability was expressed as area occupancy (n=4).

[0073] As shown in FIG. 8, antibody 7H8 (IgM) significantly inhibited the proliferation of PANC-1 cells compared to control IgM.

[0074] Test Example 5 (1) Obtaining Mouse Antibody 7H8 (IgG) To convert antibody 7H8 (IgM) to IgG, a heavy chain variable region (H1: SEQ ID NO: 4) and two light chain variable regions (L1: SEQ ID NO: 5, L2: SEQ ID NO: 6) were designed using conventional CDR grafting techniques. H1 was inserted into a vector containing the mouse IgG2a constant region, and L1 or L2 was inserted into a vector containing the human IgG1κ constant region to construct the respective antibody expression vectors. Next, the two combinations of antibody expression vectors were simultaneously transfected into ExpiHEK293F cells, and the cells were cultured for 7 days, and the supernatant was obtained.

[0075] (2) Confirmation of antibody 7H8 (IgG) expression The supernatant obtained in (1) was affinity purified using a Protein G column. After desalting and concentration, the expression of antibody 7H8-IgG was confirmed by SDS-PAGE and CBB staining. As shown in Figure 8, heavy and light chain bands were observed at the target size, indicating that antibody 7H8-IgG was contained in the supernatant.

[0076] Test Example 6: To evaluate the performance of antibody 7H8-IgG, the KD value was calculated. Using Octet RED (SARTORIUS), His-tagged recombinant HSP70 was bound to a nickel sensor, and a kinetic assay was performed at four antibody solution concentrations (0.781, 1.56, 3.13, and 6.25 nM), with binding phase / dissociation phase: 600 sec / 600 sec, 30°C, and 1,000 rpm, and the assay was analyzed by global fitting. As shown in Figure 9, the KD value of antibody 7H8-IgG was 4.60 x 10 -10 It was M.

[0077] Test Example 7 (1) Obtaining humanized antibody 7H8 To humanize the mouse antibody 7H8 (IgG), conventional CDR grafting techniques were used to design SEQ ID NO: 13 (H1), which contains a heavy chain variable region, and SEQ ID NOs: 14 and 15 (L1 and L2), which contain two light chain variable regions, respectively. H1 was inserted into a vector containing the constant region of human IgG1, and L1 or L2 was inserted into a vector containing the constant region of human IgG1κ, to construct the respective antibody expression vectors.

[0078] Next, the two combinations of antibody expression vectors were simultaneously transfected into HEK293 cells, and the cells were cultured for 4 days, after which the supernatants were obtained (referred to as humanized antibody 7H8-H / L1 and humanized antibody 7H8-H / L2, respectively).

[0079] (2) Confirmation of Expression of Humanized Antibody 7H8 The expression of humanized antibody 7H8 was confirmed by dot blotting. First, 2 μL of the supernatant obtained in (1) was adsorbed onto a nitrocellulose membrane. As a standard, human IgG1 at various concentrations was similarly adsorbed and air-dried. Next, after blocking with a buffer containing BSA, the nitrocellulose membrane was reacted with an alkaline phosphatase-labeled goat anti-human IgG solution at room temperature for 1 hour. After washing, an alkaline phosphatase substrate was added to the nitrocellulose membrane to develop color. The color development results are shown in Figure 10. As shown in Figure 10, the supernatant contained humanized antibodies 7H8-H / L1 and 7H8-H / L2.

[0080] (3) Confirmation of antigen binding of humanized antibody 7H8. Human pancreatic cancer cell line PANC-1 cells were allowed to survive long-term exposure to the anticancer drug gemcitabine to obtain gemcitabine-resistant PANC-1 cells. Gemcitabine-resistant PANC-1 cells were fixed with 3% paraformaldehyde and blocked with PBS(-) containing 1% BSA and 10% goat serum at room temperature for 30 minutes. The supernatant obtained in (1) was then added and incubated overnight at 4°C. For comparison, mouse 7H8 (IgM) was also incubated in the same manner. After washing, anti-human IgG-PE or anti-mouse IgM-Alexa488 was added and incubated at room temperature for 1 hour, followed by washing and observation under a fluorescent microscope. The observation results are shown in Figure 11. As shown in Figure 11, the humanized antibody 7H8 (IgG) in the supernatant reacted with gemcitabine-resistant PANC-1 cells with a fluorescence intensity comparable to that of mouse 7H8 (IgM), indicating that it retained its antigen-binding ability.

[0081] (4) Large-scale purification of humanized antibody 7H8. The results of (1) to (3) confirmed the expression of humanized antibody 7H8 and its binding to the antigen, so large-scale purification was carried out. Expi CHO cells (1.8 × 10 8 12.5 μg each of humanized antibodies 7H8-H, -L1, and -L2 were transfected into the cells (30 mL of medium) and cultured with shaking at 32°C for 12 days to prepare a culture medium expressing humanized antibodies 7H8-H / L1 and 7H8-H / L2. The culture medium was centrifuged and filtered to obtain the supernatant, after which Ab-Capcher was added and the mixture was rotated and mixed at 4°C for 1 hour. Next, after washing the Ab-Capcher, humanized antibody 7H8 was eluted with Gentle Ag / Ab Elution Buffer. The eluate was dialyzed three times against 1 L of PBS(-) and then concentrated by ultrafiltration. The concentrate was stained with CBB to confirm that it was a highly pure antibody. The protein concentrations were measured, and it was found that approximately 5 mg of humanized antibody 7H8-H / L1 and approximately 2 mg of humanized antibody 7H8-H / L2 were prepared from 30 mL of medium.

Claims

1. An anti-Hsp70 antibody that recognizes a region of the Hsp70 protein corresponding to positions 461 to 490 of SEQ ID NO:

1.

2. The anti-Hsp70 antibody of claim 1, which binds to Hsp70 on a cell membrane.

3. An anti-Hsp70 antibody having, as heavy chain complementarity determining regions, an HCDR1 consisting of the amino acid sequence of positions 45 to 56, 50 to 56, or 45 to 54 of SEQ ID NO:2, an HCDR2 consisting of the amino acid sequence of positions 71 to 86 or 72 to 78 of SEQ ID NO:2, and an HCDR3 consisting of the amino acid sequence of positions 117 to 128 or 119 to 128 of SEQ ID NO:2, and a light chain complementarity determining region, an LCDR1 consisting of the amino acid sequence of positions 43 to 54, 47 to 52, 50 to 52, or 50 to 53 of SEQ ID NO:3, or the amino acid sequence of positions 43 to 53 of SEQ ID NO:15, an LCDR2 consisting of the amino acid sequence of positions 70 to 76, 70 to 71, or 70 to 75 of SEQ ID NO:3, and an LCDR3 consisting of the amino acid sequence of positions 109 to 117 of SEQ ID NO:

3.

4. The anti-Hsp70 antibody according to claim 3, wherein the heavy chain variable region consists of the amino acid sequence of positions 21 to 139 of SEQ ID NO:2, and the light chain variable region consists of the amino acid sequence of positions 21 to 127 of SEQ ID NO:

3.

5. The anti-Hsp70 antibody according to claim 3, wherein the heavy chain variable region consists of the amino acid sequence of positions 21 to 139 of SEQ ID NO:13, and the light chain variable region consists of the amino acid sequence of positions 21 to 127 of SEQ ID NO:14 or the amino acid sequence of positions 21 to 127 of SEQ ID NO:

15.

6. The anti-Hsp70 antibody of claim 1, which is an isolated monoclonal antibody.

7. The anti-Hsp70 antibody of claim 6, wherein the monoclonal antibody is a human chimeric or humanized antibody.

8. An antitumor agent comprising an anti-Hsp70 antibody according to any one of claims 1 to 7.

9. The antitumor agent according to claim 8, which is applied to pancreatic cancer.

10. The antitumor agent according to claim 8, which is not used in combination with other drug therapeutic agents.

11. An antigen test kit comprising an anti-Hsp70 antibody according to any one of claims 1 to 7.

12. A nucleic acid encoding an anti-Hsp70 antibody according to any one of claims 3 to 5.

13. An expression cassette or recombinant vector comprising the nucleic acid of claim 12.

14. A transformant obtained by transforming a host with the expression cassette or recombinant vector described in claim 13.

15. A method for producing an anti-Hsp70 antibody, comprising the step of culturing the transformant according to claim 14.

Citation Information

Patent Citations

  • Anti-hsp70 antibodies for therapeutic and diagnostic use

    JP2008502314A

  • Compositions and methods for treating and diagnosing cancers

    WO2008045976A2